Niflamol (Niflumic Acid)

Niflumic Acid, the active ingredient in Niflamol, is a fenamate (nonsteroidal anti-inflammatory drug) presented as an oral tablet for oral use. It is employed to relieve mild to moderate pain and inflammation associated with musculoskeletal disorders, and is prescribed for adult patients requiring NSAID therapy.

GNH USA supplies Niflamol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Niflamol belongs to the fenamate class of NSAIDs and acts on inflammatory pathways to reduce pain and swelling. - Mild to moderate pain: provides analgesic relief for everyday aches and injuries. - Rheumatoid arthritis: helps control joint inflammation and pain in chronic autoimmune disease. - Osteoarthritis: reduces cartilage‑related discomfort and improves joint function. - Post‑operative pain: assists in managing surgical site pain during recovery.

Adverse reactions may occur with any NSAID and should be monitored.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia - Nausea or vomiting - Headache - Dizziness

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic injury or elevated liver enzymes - Renal impairment or reduced kidney function

Before prescribing Niflamol, clinicians should consider several safety measures. - Renal function assessment: evaluate kidney status, especially in patients with pre‑existing disease. - Hepatic monitoring: check liver enzymes periodically during long‑term use. - Lowest effective dose: use the minimal dose needed to achieve therapeutic effect. - Known hypersensitivity: avoid in patients with previous allergic reactions to fenamates or other NSAIDs. - Caution with anticoagulants: monitor bleeding risk when combined with warfarin or similar agents. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Niflamol may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - Lithium: elevated lithium serum levels. - Methotrexate: enhanced toxicity and reduced clearance.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible reduction in renal function. - Diuretics: heightened risk of renal impairment. - SSRIs: potential for increased bleeding tendency.